<DOC>
	<DOC>NCT00506571</DOC>
	<brief_summary>Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed every 2 cycles of chemotherapy.</brief_summary>
	<brief_title>Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirmed unresectable or metastatic colorectal cancer, not amenable to surgery or radiation treatment for curative intent At least one unidimensional measurable lesion ECOG performance status 02. No prior chemotherapy in metastatic settings, but adjuvant or neoadjuvant treatment for nonmetastatic (M0) disease is allowed if completed at least 6 months prior to initiation of study treatment Adequate major organ functions Give written informed consent Prior systemic chemotherapy for metastatic disease Prior treatment with oxaliplatin or irinotecan Prior radiotherapy is permitted if it was not administered to target lesions selected for this study and provided it has been completed at least 4 weeks before registration Prior surgical treatment of stage IV disease is permitted CNS metastases Prior history of peripheral neuropathy â‰¥ NCI CTC grade 1 Uncontrolled or severe cardiovascular disease Serious concurrent infection or nonmalignant illness Other malignancy within the past 3 years except cured nonmelanomatous skin cancer or carcinoma in situ of the cervix Organ allografts requiring immunosuppressive therapy Psychiatric disorder or uncontrolled seizure that would preclude compliance Pregnant, nursing women or patients with reproductive potential without contraception Patients receiving a concomitant treatment with drugs interacting with S1 such as flucytosine, phenytoin, or warfarin et al. Prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency Known hypersensitivity to platinum compounds or any of the components of the study medications Major surgery within 3 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>colorectal neoplasms</keyword>
	<keyword>secondary</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>